Tahir Misbah, CFO of IGM Biosciences ($IGMS), made three open market sales of company shares over the past year, totaling $21,965. His latest sale occurred on July 23, 2025. These transactions rank 10,992nd out of 11,678 insiders in our database, well below the average sale value of $8.6 million across 6.37 transactions per insider. Misbah recorded no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Tahir Misbah | Chief Financial Officer | A | Restricted Stock Units | 20000 | $0.00 | 20,000.0000 | 48,119,444 | 9999.99% | 0.04% |
| March 2, 2026 | Maze Therapeutics, Inc. | $MAZE | Tahir Misbah | Chief Financial Officer | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 48,119,444 | 9999.99% | 0.08% |
| Sept. 2, 2025 | Maze Therapeutics, Inc. | $MAZE | Tahir Misbah | Chief Financial Officer | A | Stock Option (Right to Buy) | 325000 | $0.00 | 325,000.0000 | 0 | 9999.99% | 0.00% |
| July 23, 2025 | IGM Biosciences, Inc. | $IGMS | Tahir Misbah | CHIEF FINANCIAL OFFICER | S | Common Stock | 8741 | $1.27 | 170,061.0000 | 61,816,099 | 4.89% | 0.01% |
| June 16, 2025 | IGM Biosciences, Inc. | $IGMS | Tahir Misbah | CHIEF FINANCIAL OFFICER | S | Common Stock | 1522 | $1.20 | 178,802.0000 | 60,514,546 | 0.84% | 0.00% |
| March 14, 2025 | IGM Biosciences, Inc. | $IGMS | Tahir Misbah | CHIEF FINANCIAL OFFICER | S | Common Stock | 7329 | $1.23 | 180,324.0000 | 60,514,546 | 3.91% | 0.01% |
| Dec. 16, 2024 | IGM Biosciences, Inc. | $IGMS | Tahir Misbah | CHIEF FINANCIAL OFFICER | S | Common Stock | 1708 | $7.48 | 187,653.0000 | 60,434,161 | 0.90% | 0.00% |
| Nov. 18, 2024 | IGM Biosciences, Inc. | $IGMS | Tahir Misbah | CHIEF FINANCIAL OFFICER | A | Common Stock | 66667 | $0.00 | 189,361.0000 | 60,434,161 | 54.34% | 0.11% |
| Sept. 13, 2024 | IGM Biosciences, Inc. | $IGMS | Tahir Misbah | CHIEF FINANCIAL OFFICER | S | Common Stock | 1487 | $11.54 | 122,694.0000 | 60,434,161 | 1.20% | 0.00% |
| July 19, 2024 | IGM Biosciences, Inc. | $IGMS | Tahir Misbah | CHIEF FINANCIAL OFFICER | D | Stock Option (right to buy) | 40000 | $0.00 | 0.0000 | 60,434,161 | 100.00% | 0.07% |
| July 19, 2024 | IGM Biosciences, Inc. | $IGMS | Tahir Misbah | CHIEF FINANCIAL OFFICER | D | Stock Option (right to buy) | 55000 | $0.00 | 0.0000 | 60,434,161 | 100.00% | 0.09% |
| July 19, 2024 | IGM Biosciences, Inc. | $IGMS | Tahir Misbah | CHIEF FINANCIAL OFFICER | A | Common Stock | 2222 | $0.00 | 124,181.0000 | 60,434,161 | 1.82% | 0.00% |
| July 19, 2024 | IGM Biosciences, Inc. | $IGMS | Tahir Misbah | CHIEF FINANCIAL OFFICER | A | Common Stock | 33111 | $0.00 | 121,959.0000 | 60,434,161 | 37.27% | 0.05% |
| June 14, 2024 | IGM Biosciences, Inc. | $IGMS | Tahir Misbah | CHIEF FINANCIAL OFFICER | S | Common Stock | 1570 | $7.58 | 88,848.0000 | 52,311,958 | 1.74% | 0.00% |
| March 13, 2024 | IGM Biosciences, Inc. | $IGMS | Tahir Misbah | CHIEF FINANCIAL OFFICER | S | Common Stock | 2897 | $9.88 | 92,961.0000 | 52,311,958 | 3.02% | 0.01% |
| March 14, 2024 | IGM Biosciences, Inc. | $IGMS | Tahir Misbah | CHIEF FINANCIAL OFFICER | S | Common Stock | 2543 | $10.17 | 90,418.0000 | 52,311,958 | 2.74% | 0.00% |
| March 12, 2024 | IGM Biosciences, Inc. | $IGMS | Tahir Misbah | CHIEF FINANCIAL OFFICER | A | Common Stock | 46250 | $0.00 | 95,858.0000 | 52,311,958 | 93.23% | 0.09% |
| March 12, 2024 | IGM Biosciences, Inc. | $IGMS | Tahir Misbah | CHIEF FINANCIAL OFFICER | A | Stock Option (right to buy) | 92500 | $0.00 | 92,500.0000 | 52,311,958 | 9999.99% | 0.18% |